Aroa Biosurgery Dividends and Buybacks
Dividend criteria checks 0/6
Aroa Biosurgery does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.03%
Buyback Yield
| Total Shareholder Yield | -0.03% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 04
The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
Nov 27We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Nov 13Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aug 22Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
Jun 12Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Mar 25Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Jan 30Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
Nov 14Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Nov 02Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Oct 25We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
May 13Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
May 26An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued
Mar 22Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?
Feb 24Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)
Feb 24Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price
Dec 16
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ARX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARX's dividend payments have been increasing.
Dividend Yield vs Market
| Aroa Biosurgery Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ARX) | n/a |
| Market Bottom 25% (AU) | 2.7% |
| Market Top 25% (AU) | 6.1% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (ARX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate ARX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ARX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ARX has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 15:34 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aroa Biosurgery Limited is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| John Hester | Bell Potter |
| Elyse Shapiro | Bell Potter |